U.S. flag

An official website of the United States government

GTR Home > Tests > Abnormal Mineralization Panel


Sample Negative Report


Not provided

Sample Positive Report


Not provided

Variants Of Unknown Significance (VUS) Policy And Interpretation

What is the protocol for interpreting a variation as a VUS? Help
The interpretation of a variation as a VUS is done according to the practice guidelines provided by the American College of Medical Genetics (ACMG; ACMG recommendations for standards for interpretation and reporting of sequence variations).
What software is used to interpret novel variations? Help
ALAMUT, integrating other programs (Polyphen-2, Mutation Taster, Alignment, ExPASy, BLAST) .
What is the laboratory's policy on reporting novel variations? Help
Centogene has a common practice to report all variants found in genetic testing, including novel and previously reported variants. A number of criteria are used to support a variant as being potentially disease-causing, including segregation with disease status in other affected family members, absence from a control population, and location in a conserved amino acid sequence. Evidence of altered gene function is ideally required to confirm pathogenicity, however this type of supporting evidence
Are family members with defined clinical status recruited to assess significance of VUS without charge?Help
No, We are performing a majority of carrier testing with reduced pricing and in selected cases at no cost.
Will the lab re-contact the ordering physician if variant interpretation changes? Help
Yes, In case of identification of mutation that can be present in non-affected family members, or after identification of highly specific genetic change, or in additional special situations we could contact the ordering physician again.


Is research allowed on the sample after clinical testing is complete?Help
After clinical testing is completed, with the patient’s signed consent, Centogene utilizes and archives the sample according to all regulatory guidelines and standards.

Suggested reading

  • Uitto et al., 2012
    Pseudoxanthoma Elasticum: Progress in Diagnostics and Research Towards Treatment Summary of the 2010 PXE International Research Meeting

Consumer resources

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.